RHYTHM PHARMACEUTICALS, INC. — Director's Dealing 2023

Nov 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK: 0001649904
Period of Report: 2023-11-08

Reporting Person: Lee Jennifer Kayden (EVP, Head of North America)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-11-08	Common Stock	M	5712	$6.8	Acquired	7359	Direct
2023-11-08	Common Stock	S	3479	$28.6429	Disposed	3880	Direct
2023-11-08	Common Stock	S	2233	$29.3129	Disposed	1647	Direct
2023-11-09	Common Stock	M	3438	$6.8	Acquired	5085	Direct
2023-11-09	Common Stock	S	1719	$27.3712	Disposed	3366	Direct
2023-11-09	Common Stock	S	1719	$28.00	Disposed	1647	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-11-08	Stock Option (Right to Buy)	$6.80	M	5712	Disposed	2032-02-08	Common Stock (5712)	Direct
2023-11-09	Stock Option (Right to Buy)	$6.80	M	3438	Disposed	2032-02-08	Common Stock (3438)	Direct

Footnotes

F1: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 8, 2023.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $28.04 to $29.01. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $29.04 to $29.70. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at per share prices ranging from $26.86 to $27.51. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The stock options were granted on February 9, 2022. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.